Toxicology of Drugs Developed for Cancer Patients

Award Date 7/1/2016
Last Date To Order 6/30/2021
Shared Ceiling $19M
Contract Type
Master IDIQ
Predecessor
Not listed
Successors

The National Cancer Institute's "Toxicology of Drugs Developed for Cancer Patients" Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract supports preclinical toxicology research essential to advancing potential new cancer therapies. The contract vehicle enables the Development Therapeutics Program to conduct comprehensive laboratory investigations that profile and characterize toxicological risks of experimental compounds to healthy organs. These studies are critical for generating data required by the Food and Drug Administration for Investigational New Drug Applications and for understanding potential human toxicity risks associated with emerging cancer treatments.

Task orders under this contract consistently involve detailed toxicology and pharmacology studies across various experimental compounds, typically utilizing animal models such as rats, mice, and dogs. The delivery orders range in value from approximately $15,000 to $2.4 million, with performance periods spanning 12-36 months. Prime contractors frequently include research institutes like Sri International, IIT Research Institute, Southern Research Institute, and Battelle Memorial Institute, all of which are non-profit organizations with expertise in biomedical research. The National Cancer Institute awards these cost-plus-fixed-fee contracts without small business set-aside designations, focusing instead on specialized scientific capabilities. Most studies are conducted in research facilities located in cities like Chicago, Illinois and Birmingham, Alabama, and consistently aim to support preclinical development of potential anti-cancer therapies through rigorous toxicological assessment.

Generated 1/16/25, 12:00 AM